|Day Low/High||42.59 / 46.01|
|52 Wk Low/High||33.80 / 64.94|
One big change over the last few years has been the struggle of small concerns to penetrate mass markets even with approved and superior drugs.
A look at three names to consider in the biotech and biopharma space.
Eagle Pharmaceuticals, Aratana Therapeutics and Progenics Pharmaceuticals show promise.
Eagle Pharmaceuticals, Aratana Therapeutics and Progenics Pharmaceuticals show promise ahead.
I am working incrementally into some small stocks with great long-term value.
Eagle Pharmaceuticals, Invitae and Celgene should do well this year and are attractively priced.
News announcements from these companies are supportive of continued strength.
News announcements from these companies is supportive of continued strength.
Here are three recent examples of how the patient can profit.
Solid earnings and the start of some M&A activity may be just what this sector needs to rise.
Inovio Pharmaceuticals and Eagle Pharmaceuticals both boast solid pipelines and sound balance sheets.
The market has given up a good portion of its early gains in last hour or so, while oil -- which rallied above $41 a barrel earlier today to reach a new 2016 high -- is back near $39.50. JPMorgan Chase has turned bearish on the U.S. dollar and bulli...
Markets have opened slightly higher this morning, with some stocks worth calling out. Las Vegas Sands (LVS) is continuing its recent winning streak, as Macquarie boosted outlook for companies that operate casinos in the Chinese gambling hub of Macau...
Follow these maxims and you should do well in this volatile sector.
After flying high most of the year, the biopharma company is back on my radar.
Try small stakes in several sector names to improve your odds. Also, don't trade after hours.
They have the ammunition but they keep misfiring in the market.
Here's how to lock in gains on risky small-cap biotechnology stocks.
Construction firm should benefit from sector's continuing improvement.